Siemens Healthineers' Diagnostics Margin Plunges Below 1% as Stock Flirts with 52-Week Low

Diagnostics EBIT margin falls below 1%, overshadowing £26M radiopharmacy investment and European Alzheimer's deal. Stock down 24% YTD as China pressures mount.

For investors watching Siemens Healthineers, the storm clouds are gathering in an unexpected place. While the med-tech group pours £26 million into a cutting-edge radiopharmacy in Bedfordshire and signs a European Alzheimer's initiative in Rome, its core diagnostics business is hemorrhaging profitability at an alarming rate. The EBIT margin in that division collapsed to under one percent in the second quarter — a number that has spooked the market far more than any long-term growth narrative.

The stock closed Thursday at €33.85, sliding 1.91% on the day after briefly trading higher at €34.17 in the morning. That leaves the shares nursing a year-to-date loss of roughly 24% and perched just three percent above their 52-week trough of €32.84. At its peak this year, the stock changed hands at €49.86 — a level that now looks distant, with the current price sitting more than 31% below that high. The relative strength index stands at 43.7, offering neither a buy signal nor extreme oversold conditions.

A £26m bet on cancer imaging

In Dunstable, just off the M1 motorway, construction is under way on what Siemens Healthineers describes as one of Europe’s most potent radiopharmacies. The facility will house two cyclotrons, giving it eight times the production capacity of a standard site. The location is no coincidence: the radioactive biomarkers used in PET/CT scans for early tumour detection have a short shelf life and must reach hospitals fast. The plant is expected to create up to 40 jobs and will supply the UK’s National Health Service. For a company trying to demonstrate operational momentum, this is a tangible showcase.

So too is the “MindShift” consensus paper signed in Rome on Thursday. Siemens Healthineers lent its official support to the European initiative, which outlines five priorities for Alzheimer’s care — including biological diagnosis. With around 9 million dementia patients in Europe today, a figure forecast to swell to over 14 million by 2050, the diagnostic opportunity is structural.

CEO charms, but China bites

Chief executive Bernd Montag was in London this week for the J.P. Morgan European Healthcare Forum, beating the drum for the company’s precision-medicine strategy. Yet the message appears to have fallen on deaf ears. After May’s painful guidance cut, investors want more than slide-deck promises. The real albatross is China.

Structural shifts in the world’s second-largest economy are hitting Siemens Healthineens hard. Local procurement quotas and aggressive price adjustments in laboratory diagnostics are squeezing revenue. On top of that, tariffs and inflated supply-chain costs — particularly for memory chips and logistics — are eating into margins. The diagnostics division’s EBIT margin dipping below one percent is the starkest symptom of that pressure.

Chart paints a worrying picture

The technical backdrop offers little comfort. The 200-day moving average sits well above €41, while even the 50-day line remains an imposing resistance level. The company launched a share buyback programme in early June to shore up confidence, but many analysts view it as a drop in the bucket while the China headwind persists.

A potential catalyst lies further out: Siemens Energy’s planned spin-off of its stake in Healthineers, scheduled for February 2027, could eventually unlock value. But that distant date does nothing to alter the immediate selling pressure. For now, the diagnostics margin crisis, the proximity to fresh lows, and the ineffective charm offensive in London all point to a stock that remains a falling knife — until the fundamentals begin to stabilise.